Jason Shafrin

1 day ago | healthcare-economist.com | Jason Shafrin

My Papers Pharmaceuticals Public Policy Key readings to help you evaluate a major change to US drug pricing policy On May 12, 2025, President Trump issued an executive order calling for “most favored nation” (MFN) drug pricing in the US. Key questions you may have include: ▪ What is MFN pricing? ▪ Which countries will be included in the MFN basket? ▪ How much lower are drug prices ex-US vs US? ▪ How should I evaluate MFN?

2 days ago | healthcare-economist.com | Jason Shafrin

Pharmaceuticals Public Policy Consequences of Tariffs on Pharmaceutical Products The Budget Lab at Yale University projected that a 25% ad valorem tariff would increase medication costs by an “average of around $600 per year per household in the United States.”3 Tariffs can also create supply chain disruptions, increase costs and limit patient access to essential medications, and negatively impact research and innovation.

3 days ago | healthcare-economist.com | Jason Shafrin

Uncategorized Factors That Increase Utilization Management Risk Objectives: To (1) develop a metric that quantitatively measures the risk that utilization management (UM) policies pose to patients and (2) measure the relationship between this metric and payers’ real-world UM use. Study Design: We conducted a targeted literature review and an expert elicitation exercise to create the Data-Based Utilization Management Risk Designation (BURDEN) score.

4 days ago | healthcare-economist.com | Jason Shafrin

Physician Compensation Supply of Medical Services US Physicians in 2024: More likely to work in larger, multi-specialty, PE-owned practices These are the findings from the American Medical Association’s 2024 Physician Practice Benchmark Survey. Physicians included in the survey include those who practice in the U.S., actively see patients, and have completed residency.

1 week ago | healthcare-economist.com | Jason Shafrin

Cancer My Papers ISPOR 2025 Award Winners I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the best Best General Podium Research Presentations.